Invention Grant
US08575099B2 Agent for treating polyglutamine aggregation-caused disease or suppressing onset thereof
有权
用于治疗聚谷氨酰胺聚集引起的疾病或抑制其发作的药剂
- Patent Title: Agent for treating polyglutamine aggregation-caused disease or suppressing onset thereof
- Patent Title (中): 用于治疗聚谷氨酰胺聚集引起的疾病或抑制其发作的药剂
-
Application No.: US12226447Application Date: 2007-03-30
-
Publication No.: US08575099B2Publication Date: 2013-11-05
- Inventor: Toshikazu Nakamura , Hiroshi Funakoshi , Daisuke Miyazawa , Kunio Iwatani
- Applicant: Toshikazu Nakamura , Hiroshi Funakoshi , Daisuke Miyazawa , Kunio Iwatani
- Applicant Address: JP Osaka JP Osaka
- Assignee: Osaka University,Kringle Pharma Inc.
- Current Assignee: Osaka University,Kringle Pharma Inc.
- Current Assignee Address: JP Osaka JP Osaka
- Agency: Wnderoth, Lind & Ponack, L.L.P.
- Priority: JP2006-116635 20060420
- International Application: PCT/JP2007/057218 WO 20070330
- International Announcement: WO2007/122976 WO 20071101
- Main IPC: A61K38/18
- IPC: A61K38/18 ; C07K14/47
Abstract:
The present invention discloses an agent for treating a polyglutamine aggregation-caused disease or suppressing its onset, which comprises, as an active ingredient, (1) (i) HGF protein, (ii) a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein, or a salt of either of them, or (2) DNA containing (i) DNA encoding HGF protein, (ii) DNA encoding a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein or (iii) DNA which encodes a protein or a peptide that is substantially equivalent in activity to HGF protein and hybridizes with DNA comprising a complementary base sequence of either of the above-mentioned DNAs under a stringent condition.
Public/Granted literature
- US20100168003A1 Agent for Treating Polyglutamine Aggregation-Caused Disease or Suppressing Onset Thereof Public/Granted day:2010-07-01
Information query
IPC分类:
